The essentials of HIV: A review for nurses

Journal of Infusion Nursing

Volumn 31, Issue 4, 2008, Pages 228-235

  Petroll, Andrew E ^a   Hare, C Bradley ^b   Pinkerton, Steven D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; INTEGRASE INHIBITOR; PROCHLORPERAZINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANEMIA; ANTIVIRAL RESISTANCE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIARRHEA; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; INFECTION PREVENTION; INFECTION RATE; INSOMNIA; INSULIN RESISTANCE; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER TOXICITY; NAUSEA; NEEDLESTICK INJURY; NEPHROLITHIASIS; NONHUMAN; NUCLEIC ACID AMPLIFICATION; NURSE; OCCUPATIONAL EXPOSURE; PANCREATITIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SKIN NODULE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; VIRUS TRANSMISSION; VOMITING; WESTERN BLOTTING; DISEASE TRANSMISSION; NURSING;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HUMANS; OCCUPATIONAL EXPOSURE; UNITED STATES;

EID: 53449099750     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAN.0000326831.82526.c4     Document Type: Review

References (35)

1. UNAIDS. 2007 AIDS epidemic update. http://data.unaids.org/pub/EPISlides/ 2007/2007-epiupdate-en.pdf. Accessed June 2, 2008.
2. UNAIDS. AIDS epidemic update. http://data.unaids.org/pub/EpiReport/2006/ 2006-EpiUpdate-en.pdf. Published December 2006. Accessed October 16, 2007.
3. Glynn M, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003. Paper presented at: National HIV Prevention Conference; June 12-15, 2005; Atlanta, GA.
4. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 2005. Vol 17. Rev ed. Atlanta: Centers for Disease Control and Prevention; 2007:16-17.
5. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975-979.
6. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Vol 9. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 1997:22.
7. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2005. Vol 17. Rev ed. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2007:16-17.
8. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 2001;15:1329-1341.
9. San Antonio-Gaddy M, Richardson-Moore A, Burstein GR, et al. Rapid HIV antibody testing in the New York State anonymous HIV counseling and testing program. J Acquir Immune Defic Syndr. 2006;43:446-450.
10. Kendrick SF, Kroc KA, Withum D, et al. Outcomes of offering rapid point-of-care HIV testing in a sexually transmitted disease clinic. J Acquir Immune Defic Syndr. 2005;38:142-146.
11. Wurcel A, Zama T, Zhen S, Stone D. Acceptance of HIV antibody testing among inpatients and outpatients at a public health hospital: a study of rapid versus standard testing. AIDS Patient Care STDs. 2005;19:499-505.
12. Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Morb Mortal Wkly Rep. 2006;55(RR-14):1-17.
13. Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier Saunders; 2005.
14. Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS Behav. Accepted November 5, 2007. Published online December 7, 2007.
15. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990;335:123-128.
16. Mbulaeiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003;32:527-533.
17. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285;1736-1745.
18. Wilson IB, Landon BE, Hirschhorn LR. Quality of HIV care provided by nurse practitioners, physician assistants, and physicians. Ann Intern Med. 2005;143:729-736.
19. Grubb JR, Singhatiraj E, Mondy K, et al. Patterns of primary antiretroviral drug resistance in antiretroviral-naïve HIV-1-infected individuals in a midwest university clinic. AIDS. 2006;20:2115-2125.
20. Novak RM, Chen L, MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naïve patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40:468-474.
21. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naïve HIV-1-infected persons in 10 US cities. J Infect Dis. 2004;189:2174-2180.
22. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
23. Manheimer S, Griedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-1121.
24. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
25. The Strategies for Management of Antiretroviral Therapy (SMART) study group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
26. Panlilio AL, Orelien JG, Srivastava PU, et al. Estimate of the annual number of percutaneous injuries among hospital-based healthcare workers in the United States, 1997-1998. Infect Control Hosp Epidemiol. 2004;25:556-562.
27. Centers for Disease Control and Prevention. Surveillance of occu-pationally acquired HIV/AIDS in healthcare personnel, as of December 2006. http://www.cdc.gov/ncidod/dhqp/pdf/bbp/fact-sheet-clearance-revised- 090507Dec2006.pdf. Published 2007. Accessed October 12, 2007.
28. Bell D. Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med. 1997;102(5B):9-15. (Pubitemid 27334739)
29. Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 2005;54:1-17.
30. Sulkowski MS, Ray SC, Thomas DL. Needlestick transmission of hepatitis C. JAMA. 2002;287:2406-2413.
31. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337:1485-1490.
32. Centers for Disease Control and Prevention. Updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep. 2005;54(RR-9):1-17.
33. Roland ME. Postexposure prophylaxis after sexual exposure to HIV. Curr Opin Infect Dis. 2007;20:39-46.
34. Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. MMWR Morb Mortal Wkly Rep. 2005;54(RR-2):1-20.
35. Lohse N, Hanse AE, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146:87-95.